USS Investment Management Ltd Has $20.03 Million Stock Holdings in Bristol-Myers Squibb (NYSE:BMY)

USS Investment Management Ltd decreased its stake in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 11.7% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 353,836 shares of the biopharmaceutical company's stock after selling 46,833 shares during the quarter. USS Investment Management Ltd's holdings in Bristol-Myers Squibb were worth $20,025,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in BMY. Vanguard Group Inc. lifted its holdings in Bristol-Myers Squibb by 0.7% during the 4th quarter. Vanguard Group Inc. now owns 189,944,516 shares of the biopharmaceutical company's stock worth $10,743,262,000 after buying an additional 1,373,209 shares in the last quarter. Capital International Investors raised its holdings in shares of Bristol-Myers Squibb by 7.5% during the fourth quarter. Capital International Investors now owns 45,866,624 shares of the biopharmaceutical company's stock worth $2,593,940,000 after acquiring an additional 3,218,865 shares during the period. Geode Capital Management LLC lifted its stake in Bristol-Myers Squibb by 2.7% in the 4th quarter. Geode Capital Management LLC now owns 44,391,247 shares of the biopharmaceutical company's stock valued at $2,505,967,000 after acquiring an additional 1,187,231 shares in the last quarter. Norges Bank acquired a new stake in Bristol-Myers Squibb in the 4th quarter valued at $1,989,525,000. Finally, Ameriprise Financial Inc. grew its stake in Bristol-Myers Squibb by 59.9% in the fourth quarter. Ameriprise Financial Inc. now owns 32,079,246 shares of the biopharmaceutical company's stock valued at $1,814,341,000 after purchasing an additional 12,011,983 shares in the last quarter. Institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on BMY shares. Wells Fargo & Company boosted their target price on shares of Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an "equal weight" rating in a report on Friday, February 7th. Piper Sandler initiated coverage on shares of Bristol-Myers Squibb in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price objective on the stock. Jefferies Financial Group cut their target price on shares of Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating for the company in a research note on Wednesday, April 23rd. Cantor Fitzgerald reissued a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a research report on Tuesday, April 22nd. Finally, The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price objective (down from $67.00) on shares of Bristol-Myers Squibb in a research report on Tuesday, April 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have assigned a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $58.00.

Insiders Place Their Bets

In related news, EVP Samit Hirawat bought 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, for a total transaction of $202,215.00. Following the transaction, the executive vice president now owns 83,513 shares in the company, valued at $3,973,548.54. The trade was a 5.36% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Stock Performance

Shares of BMY traded down $0.15 during midday trading on Monday, reaching $46.88. 8,401,343 shares of the stock were exchanged, compared to its average volume of 13,150,161. The stock's 50 day simple moving average is $51.79 and its 200 day simple moving average is $55.72. The company has a market cap of $95.40 billion, a P/E ratio of -10.61, a PEG ratio of 2.07 and a beta of 0.39. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.30. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business had revenue of $11.20 billion during the quarter, compared to analysts' expectations of $10.77 billion. During the same quarter in the previous year, the company earned ($4.40) EPS. The business's revenue was down 5.6% on a year-over-year basis. On average, sell-side analysts expect that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 1st. Investors of record on Friday, April 4th were given a dividend of $0.62 per share. This represents a $2.48 dividend on an annualized basis and a yield of 5.29%. The ex-dividend date was Friday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently 92.88%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.